



Identification of non-HLA genes associated with development of islet autoimmunity and type 1 diabetes in the prospective TEDDY cohort

Ashok Sharma ^{a, m}, Xiang Liu ^b, David Hadley ^c, William Hagopian ^d, Wei-Min Chen ^e, Suna Onengut-Gumuscu ^e, Carina Törn ^f, Andrea K. Steck ^g, Brigitte I. Frohnert ^g, Marian Rewers ^g, Anette-G. Ziegler ^{h, i, j}, Åke Lernmark ^f, Jorma Toppari ^k, Jeffrey P. Krischer ^b, Beena Akolkar ^l, Stephen S. Rich ^e, Jin-Xiong She ^{a, *}, for the TEDDY Study Group ¹

^a Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA

^b Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

^c Division of Population Health Sciences and Education, St George's University of London, London, United Kingdom

^d Pacific Northwest Research Institute, Seattle, WA, USA

^e Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

^f Department of Clinical Sciences, Lund University/CRC, Malmö, Sweden

^g Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Aurora, CO, USA

^h Institute of Diabetes Research, Helmholtz Zentrum München, Munich-Neuherberg, Germany

ⁱ Klinikum rechts der Isar, Technische Universität München, Munich-Neuherberg, Germany

^j Forschergruppe Diabetes e.V., Munich-Neuherberg, Germany

^k Department of Pediatrics, Turku University Hospital, Turku, Finland

^l National Institutes of Diabetes and Digestive and Kidney Disorders, National Institutes of Health, Bethesda, MD, USA

^m Division of Biostatistics and Data Science, Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA

ARTICLE INFO

Article history:

Received 5 November 2017

Received in revised form

5 December 2017

Accepted 6 December 2017

Available online 5 January 2018

Keywords:

TEDDY study

Autoimmune disorder

Gene mapping

Susceptibility

Type 1 diabetes

ABSTRACT

Traditional linkage analysis and genome-wide association studies have identified HLA and a number of non-HLA genes as genetic factors for islet autoimmunity (IA) and type 1 diabetes (T1D). However, the relative risk associated with previously identified non-HLA genes is usually very small as measured in cases/controls from mixed populations. Genetic associations for IA and T1D may be more accurately assessed in prospective cohorts. In this study, 5806 subjects from the TEDDY (The Environmental Determinants of Diabetes in the Young) study, an international prospective cohort study, were genotyped for 176,586 SNPs on the ImmunoChip. Cox proportional hazards analyses were performed to discover the SNPs associated with the risk for IA, T1D, or both. Three regions were associated with the risk of developing any persistent confirmed islet autoantibody: one known region near *SH2B3* (HR = 1.35, $p = 3.58 \times 10^{-7}$) with Bonferroni-corrected significance and another known region near *PTPN22* (HR = 1.46, $p = 2.17 \times 10^{-6}$) and one novel region near *PPIL2* (HR = 2.47, $p = 9.64 \times 10^{-7}$) with suggestive evidence ($p < 10^{-5}$). Two known regions (*PTPN22*: $p = 2.25 \times 10^{-6}$, *INS*: $p = 1.32 \times 10^{-7}$) and one novel region (*PXK/PDHB*: $p = 8.99 \times 10^{-6}$) were associated with the risk for multiple islet autoantibodies. First appearing islet autoantibodies differ with respect to association. Two regions (*INS*: $p = 5.67 \times 10^{-6}$ and *TTC34/PRDM16*: 6.45×10^{-6}) were associated if the first appearing autoantibody was IAA and one region (*RBFOX1*: $p = 8.02 \times 10^{-6}$) was associated if the first appearing autoantibody was GADA. The analysis of T1D identified one region already known to be associated with T1D (*INS*: $p = 3.13 \times 10^{-7}$) and three novel regions (*RNASET2*, *PLEKHA1*, and *PPIL2*; $5.42 \times 10^{-6} > p > 2.31 \times 10^{-6}$). These results suggest that a

Abbreviations: SNP, Single-nucleotide polymorphism; TEDDY, The Environmental Determinants of Diabetes in the Young; IA, Islet autoimmunity; T1D, type 1 diabetes; MAF, minor allele frequency.

* Corresponding author. Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912, USA.

E-mail address: jshe@augusta.edu (J.-X. She).

¹ A complete list of the TEDDY Study Group can be found in the [Supplementary Appendix online](#).

number of low frequency variants influence the risk of developing IA and/or T1D and these variants can be identified by large prospective cohort studies using a survival analysis approach.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Type 1 Diabetes (T1D) is a multifactorial disease where multiple genes and environmental factors interact in a complex manner to cause the disease. HLA-DR-DQ is known to be the most important genetic factor and a number of non-HLA genes also influence the risk for islet autoimmunity (IA) and clinical disease. Autoantibodies are detectable very early in life and the age and order of occurrence of islet autoantibodies is associated with genetic backgrounds [1]. Most previous genetic studies focused on the clinical disease as the phenotype while few studies focus on IA as an endpoint [2–4]. Previous TEDDY, DAISY and DIPP studies that looked at development of IA and progression from IA to T1D were limited to the known non-HLA genes [4–6]. Interestingly, a previous study has shown associated genes for IA and T1D are not completely overlapping [5]. It is well known that IA is an intermediate phenotype for T1D and not all subjects with autoantibodies will progress to clinical disease within a given time frame. Genetic factors may act at various stages of the disease development, with some genes playing a role in IA development and others playing a critical role in the rate of subsequent disease progression. Therefore, it is important to analyze both stages to fully understand the contribution of genetic factors to the pathogenesis of islet autoimmunity and T1D.

With a few exceptions, all previous genetic studies of T1D used a case-control or family study design. However, cohorts with longitudinal data for survival analysis may be a much more powerful approach to identify genetic factors [7]. The Environmental Determinants of Diabetes in the Young (TEDDY) is a large international prospective cohort study, in which newborns from the US and European general populations and first-degree relatives of T1D patients were screened for specific HLA genotypes. Children with one of nine HLA DR-DQ genotypes associated with increased risk for T1D are followed in a 15 year prospective follow-up study [8]. Furthermore, a major finding in TEDDY is the observation that the first appearing islet autoantibody differ with respect to type and association with HLA. First, IAA as first appearing autoantibody was associated with HLA DR4-DQ8 while GADA first was primarily associated with DR3-DQ2 [1,9]. The incidence rate of IAA first differed from GADA first [1,9]. Also, while IAA first was associated with history of upper respiratory infection, that of GADA first showed a relationship to maternal reported infections dependent of the CTLA-4 genotype of the child [10]. To identify genes associated with T1D, we genotyped 176,586 SNPs in the regions containing autoimmunity and inflammatory response genes using the ImmunoChip.

SNP data were analyzed using Cox proportional hazards analyses to discover the genetic regions influencing the development of IA and/or T1D. Any persistent confirmed islet autoantibody, either IAA first or GADA first, multiple islet autoantibodies (two or more persistent confirmed islet autoantibodies) and T1D were the five outcomes analyzed in this study. Overall, we identified 6 novel regions with suggestive evidence ($9.0 \times 10^{-6} < p < 9.6 \times 10^{-7}$), and confirmed 3 regions with previously known associations. We also found that different genetic regions were associated to IAA or GADA as the first appearing indication of autoimmunity.

2. Material and methods

2.1. Material

A total of 424,788 newborn children in Finland, Sweden, Germany and the United States (Colorado, Georgia and Washington) were screened for high-risk genotypes for T1D as previously described [11]. Of these, 21,589 had one of nine selected HLA genotypes associated with increased risk for T1D and 8676 eligible children (Supplemental Figure-1) were enrolled to a 15-year prospective follow-up [8]. The TEDDY study was performed according to the principles of the Declaration of Helsinki. Written informed consents were obtained for all study participants from a parent or primary caretaker, separately, for genetic screening and for participation in prospective follow-up. The study was approved by local Institutional Review Boards at 6 clinical research centers (3 in the United States and 3 in Europe): University of Colorado Denver, Augusta University, Pacific Northwest Diabetes Research Institute, Turku University Hospital (Finland), Institute of Diabetes Research (Germany), and Lund University (Sweden). The study is also monitored by an external evaluation committee formed by the National Institutes of Health.

2.2. Assessment of study outcomes: islet autoimmunity and type 1 diabetes

The development of islet autoimmunity (presence of GADA, IA-2A and mIAA autoantibodies in serum) was assessed every three months in two reference laboratories using radioimmuno-binding assays [12–15]. In the U.S., all sera were assayed at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver; in Europe, all sera were assayed at the University of Bristol, U.K. All samples positive for autoantibodies and 5% of samples negative for islet autoantibodies were re-tested for confirmation in both reference laboratories. Islet autoimmunity (IA) was defined by the presence of persistent confirmed autoantibody for any of three islet autoantibodies (GADA, IA-2A or mIAA) on two or more consecutive visits. The date of any persistent confirmed islet antibody was defined as the draw date of the first of two consecutive samples at which the child was confirmed as “positive” for any autoantibody. The date of multiple islet autoantibodies was defined by the first date when at least two confirmed islet autoantibodies were detected. T1D diagnosis was based on American Diabetes Association criteria [16].

2.3. SNP genotyping by ImmunoChip

SNPs were genotyped by the Center for Public Health Genomics at University of Virginia, using the Illumina ImmunoChip Infinium array. Genotype calling and quality control steps were applied to the dataset: (1) individuals with low call rate (<95%), or discordance with reported gender and prior genotyping were not considered in the analysis, (2) SNP markers with low call rates (<95%) were excluded, and (3) markers with allele distributions strongly deviating from Hardy-Weinberg equilibrium in controls

($p < 10^{-6}$) were discarded (except for chromosome 6 due to HLA eligibility requirements). The numbers of excluded SNPs and subjects for each quality control step are provided in supplementary data (Supplemental File: S2).

2.4. Statistical analysis

Cox proportional hazards modeling was used to analyze the effect of each individual SNP (by genotype category 0,1,2) on the risk of developing each of three outcomes (any islet autoantibody, multiple islet autoantibody and T1D), adjusting for country of residence (as strata), sex, family history (first-degree relative) of T1D, HLA-DR-DQ genotype (e.g., DR3/4, DR4/4, DR4/8, DR3/3 and others) [8], HLA-DPB1 genotype, and the top six principal components from ImmunoChip data to account for population stratification (ancestral heterogeneity). The Cox models were fitted using the “survival” package in R 3.2.5 [17]. As the majority of the subjects were Caucasians, and to reduce population stratification further, subjects from other races were excluded and analyses were restricted to the self-reported Caucasians. All subjects from Finland and Sweden were included in the analysis due to the lack of data on ethnicity. However, principal component analysis suggested that Finland and Sweden populations are homogeneous and overlapping with Caucasian cluster. Only one child per family was kept in the analyses. As a result, 5806 subjects were included in the final analysis. Data were analyzed to discover the SNPs associated with five outcomes: (i) time to any persistent confirmed islet autoantibody (time-to-IA), (ii) time to multiple autoantibodies (time-to-multiple IA), (iii) time to IAA as the first appearing antibody, (iv) time to GADA as the first appearing antibody and (v) time to type 1 diabetes (time-to-T1D).

From the 176,586 SNPs that passed quality control filters, the analysis focused on those 131,847 with minor allele frequencies (MAFs) of at least 0.01; thus, chip-wide statistical significance for any single SNP required a Bonferroni-corrected $p < 3.7 \times 10^{-7}$. Significance with suggestive evidence was claimed if $p < 10^{-5}$. A web-based plotting tool *locuszoom* [18] was used to plot HapMap CEU linkage disequilibrium r^2 values for proximal SNPs in the discovered genomic regions.

3. Results

As of March 31, 2017, the median (interquartile range (IQR)) age at the last follow up of the 5806 children was 8.3 (5.5–10.0) years. A total of 587 children (10.1%) developed any persistent confirmed islet autoantibody at the median (IQR) age of 2.8 (1.5–5.5) years. In 224 children, the first appearing confirmed persistent autoantibody was IAA and in 247 children it was GADA. The remaining 116 children had multiple autoantibodies or IA-2A as the first appearing autoantibody. Furthermore, 352 children (6.1%) developed multiple persistent confirmed islet autoantibodies at the median (IQR) age of 2.8 (1.6–5.1) years and 209 children developed T1D at the median (IQR) age of 4.9 (2.7–7.5) years.

3.1. SNPs associated with development of any persistent confirmed islet autoantibody

The results from the Cox proportional hazards analyses of the 131,847 SNPs on the risk of developing any persistent confirmed islet autoantibody are presented in Fig. 1. One of these SNPs near *SH2B3* region attained chip-wide association significance, 12 SNPs (Supplemental Table-3) mapped to 3 different regions showed suggestive evidence ($p < 10^{-5}$). Out of these 13 SNPs, 12 SNPs mapped to 2 previously reported T1D regions: rs6679677/*PTPN22* (HR = 1.46; $p = 2.17 \times 10^{-6}$); rs3184504/*SH2B3* (HR = 1.35;

$p = 3.58 \times 10^{-7}$) (Table 1) and 1 SNP mapped to a novel region, previously not known to be associated with T1D: rs428595/*PPIL2* (HR = 2.47; $p = 9.64 \times 10^{-7}$). The Kaplan-Meier plots for the lead SNPs with smallest p-values from these 3 regions are shown in Fig. 1B. The novel candidate SNP near *PPIL2* (rs428595) associated with any persistent confirmed islet autoantibody requires further studies to confirm the association. Regional association plots reflecting other nearby genes in these 3 regions are shown in supplementary data (Supplemental File: S4).

3.2. SNPs associated with IAA or GADA as the first appearing islet autoantibody

The analysis was divided into either IA-IAA only or IA-GADA only. If the first appearing autoantibody was IAA, it was found that two regions: rs3842727/*INS* (HR = 0.57; $p = 5.67 \times 10^{-6}$) and rs28600853/*TTC34/PRDM16* (HR = 3.23; $p = 6.45 \times 10^{-6}$) were associated with suggestive evidence (Table 2). These two regions were not significant in the GADA as first antibody analysis ($p = .25$ and $.53$ respectively). In contrast, only one region: rs9934817/*RBFOX1* (HR = 2.66; $p = 8.02 \times 10^{-6}$) was found to be associated if the first appearing autoantibody was GADA (Table 2) and this region was not significant in the IAA as first antibody analysis ($p = .61$). These results show that there are different genetic factors associated to IAA or GADA as the first appearing islet antibody. Regional association plots reflecting other nearby genes in these 3 regions are shown in supplementary data (Supplemental File: S4).


3.3. SNPs associated with development of multiple islet autoantibodies

The analysis results of developing multiple islet autoantibodies are presented in Fig. 2. One of these SNPs near *INS/TH* region attained chip-wide association significance ($p = 1.32 \times 10^{-7}$), 6 SNPs (Supplemental Table-3) mapped to 3 different regions showed suggestive evidence ($P < 10^{-5}$). Two out of these 3 regions are previously reported T1D regions: rs6679677/*PTPN22* (HR = 1.59; $p = 2.25 \times 10^{-6}$); rs3842727/*INS* (HR = 0.50; $p = 3.13 \times 10^{-7}$) and 1 region is a novel region, previously not known to be associated with T1D: rs11705721/*PXK/PDHB* (HR = 1.41; $p = 8.99 \times 10^{-6}$) (Table 1). The novel candidate SNP near *PPIL2* (rs428595) also showed a strong association with the risk of multiple islet autoantibodies (HR = 2.72; $p = 1.06 \times 10^{-5}$). The Kaplan-Meier plots for the lead SNPs with smallest p-values from these 4 regions are shown in Fig. 2B. Regional association plots for these 4 regions are shown in supplementary data (Supplemental File: S4).

3.4. SNPs associated with development of T1D

In time-to-T1D analyses, one region previously known to be associated with T1D near *INS* reached the chip-wide significance threshold (HR = 0.504; $p = 3.13 \times 10^{-7}$), and three other novel regions reached the threshold for suggestive evidence ($p < 10^{-5}$): rs73043122/*RNASET2* (HR = 3.35; $p = 4.06 \times 10^{-6}$); rs113306148/*PLEKHA1* (HR = 3.07; $p = 2.54 \times 10^{-6}$), and rs428595/*PPIL2* (HR = 3.42; $p = 2.31 \times 10^{-6}$) (Table 1). The analysis results of T1D are presented in Fig. 3. The Kaplan-Meier plots for the lead SNPs with smallest p-values from these 1 known and 3 novel regions are shown in Fig. 3B. Data for nearby SNPs in each region with the most significant SNPs and genes are shown in the regional association LocusZoom plots (Supplemental File: S4).

A: time-to-IA Manhattan plot



B: K-M Plots




Fig. 1. Associations with risk of any persistent confirmed islet autoantibody (IA). A: Manhattan plot of 131,847 SNPs with MAF>0.01, displaying the p -values on the $-\log_{10}$ scale for SNP associations with islet autoimmunity. Hazard Ratios and p -values are calculated using the Cox proportional hazards model to analyze each SNP's effect on the risk of IA with adjustment for family history of T1D, HLA-DR-DQ genotype, gender, *HLA-DPB1*, population stratification (ancestral heterogeneity) and country of residence (as strata). The dashed line represents $p = 1 \times 10^{-5}$, the solid line represents Bonferroni correction threshold ($p = 3.7 \times 10^{-7}$). B: Kaplan-Meier plot of the most significant SNP associated from 2 known (*PTPN22*, *SH2B3*) and 1 novel (*PPIL2*) regions are plotted by dividing the subjects in two groups: (i) Major homozygous (black curves) and (ii) Heterozygous combined with minor homozygous (red curves).

3.5. Fine mapping of six novel regions

Six novel regions were further examined for nearby SNPs. The first novel region near the *PPIL2* gene on chromosome-22 (22q11.21) was found to be associated with development of any islet autoantibody, multiple islet autoantibodies, as well as T1D with suggestive evidence. In addition to the SNP rs428595, five other proximal SNPs showed $p < 10^{-4}$ in time-to-T1D analyses. LocusZoom plots of this region are shown in Fig. 4A (time-to-IA) and 4E (time-to-T1D). Other nearby genes in the region include

UBE2L3, *MAPK1*, *YDJC*, *YPEL1*, *CCDC116*, *SDF2L1* and two microRNAs (*MIR301B* and *MIR130B*). The second novel region is on chromosome-3 (3p14.3) near *PXK/PDHB* genes. LocusZoom plots of this region are shown in Fig. 4B and other nearby genes in the region include *ABHD6*, *RPP14*, *PDHB*, *KCTD6* and *ACO2*. The third novel region is 6q27 on chromosome-6. As shown in Fig. 4C, genes in this region include *RNASET2*, *CCR6*, *RPS6KA2-AS1*, *GPR31*, *TCP10L2*, *FGFR1OP* and microRNA *MIR3939*. We found at least one SNP with suggestive evidence ($p < 10^{-5}$) and several SNPs with $p < 10^{-4}$ mapped to these three regions (*PPIL2*, *PXK*, *RNASET2*). The most

Table 1
Lead SNP associations with IA and T1D ($p < 10^{-5}$), mapped to previously known and novel regions.

Region	Genes	SNP*	Major/Minor allele	CHR	BP	MAF	HR-IA	p-value	HR-Multiple	p-value IA	HR-T1D	p-value
Previously Known Regions												
1	PTPN22	rs6679677	C/A	1p13.2	114105331	0.113	1.457	2.17E-06	1.592	2.25E-06	1.635	1.24E-04
2	INS/TH	rs3842727	A/C	11p15.5	2141424	0.284	0.746	2.82E-05	0.601	1.32E-07	0.504	3.13E-07
3	SH2B3	rs3184504	G/A	12q24.12	110368991	0.462	1.353	3.58E-07	1.301	5.58E-04	1.166	1.21E-01
Novel Regions**												
1	PXK/PDHB	rs11705721	A/G	3p14.3	58375454	0.321	1.272	8.03E-05	1.410	8.99E-06	1.322	5.66E-03
2	RNASET2/MIR3939	rs73043122	G/C	6q27	167303257	0.013	1.415	1.28E-01	1.919	1.12E-02	3.351	4.06E-06
3	PLEKHA1/MIR3941	rs113306148	G/A	10q26.13	124149828	0.013	1.965	2.59E-04	2.463	2.00E-05	3.067	2.54E-06
4	PPIL2	rs428595	G/A	22q11.21	20346391	0.011	2.468	9.64E-07	2.720	1.06E-05	3.424	2.31E-06

CHR: Chromosome; BP: Base Pair Position (NCBI 36.3); MAF: Minor Allele Frequency; HR-IA: Hazard Ratio in islet autoimmunity analysis; HR-MIA: Hazard Ratio in multiple islet autoimmunity analysis; HR-T1D: Hazard Ratio in T1D analysis.

*The data for the SNP with smallest p-value is presented from each region. HRs and p-value adjusted for family history of T1D, HLA-DR-DQ genotype, gender, *HLA-DPB1*, population stratification (ancestral heterogeneity) and country of residence (as strata).

** 1. *PXK* was previously associated with susceptibility to systemic lupus erythematosus [19].

2. *RNASET2* gene is known to be associated with Graves disease and vitiligo [34–36].

3. A recent proteome-scale profiling study identified *PPIL2* as a novel T1D-associated autoantigens [23].

4. In a recent study, *PLEKHA1* has been associated with T1D with supplementary evidence ($p < 10^{-4}$) [43].

Table 2
Lead SNP associations ($p < 10^{-5}$) with either IAA or GADA as first appearing islet autoantibodies.

Region	Genes	SNP*	Major/Minor allele	CHR	BP	MAF	HR IAA- First	p-value	HR GADA- First	p-value	Known/Novel
1	<i>TTC34/PRDM16</i>	rs28600853	A/G	1p36.3	2769620	0.011	3.233	6.45E-06	0.728	.529	Novel
2	<i>INS/TH</i>	rs3842727	A/C	11p15.5	2141424	0.284	0.571	5.67E-06	1.119	.252	Known
3	<i>RBFOX1</i>	rs9934817	A/G	16p13.3	6076220	0.019	1.181	.605	2.663	8.02E-06	Novel

CHR: Chromosome; BP: Base Pair Position (NCBI 36.3); MAF: Minor Allele Frequency; HR-IAA-First: Hazard Ratio in IAA as first islet autoimmunity analysis; HR-GAD First: Hazard Ratio in GADA as islet autoimmunity analysis.

* The data for the SNP with smallest p-value is presented from each region. HRs and p-value adjusted for family history of T1D, HLA-DR-DQ genotype, gender, *HLA-DPB1*, population stratification (ancestral heterogeneity) and country of residence (as strata).

significant SNPs from these regions are in high linkage disequilibrium ($r^2 > 0.80$) with each other. Another novel region found in time-to-T1D analysis is near *PLEKHA1/MIR3941* on chromosome 10 (10q26.13). Nearby genes in the region are: *BTBD16*, *ARMS2*, *HTRA1* and *DMBT1*. However only one SNP (rs113306148) was mapped to this region (Fig. 4D). One novel region near *TTC34* and *PRDM16* genes was associated to IAA as the first appearing islet antibody. Other nearby genes in this region are: *MMEL1*, *TNFRSF14* and *ACTRT2*. One novel SNP (rs9934817) within *RBFOX1* gene was associated to GADA as the first appearing islet antibody.

4. Discussion

Although the genes in the HLA region comprise the most important genetic risk for T1D, other non-HLA genes also contribute to the development of autoantibodies and clinical diabetes. Several non-HLA genes have been associated with T1D with modest effect size [19–21]. In our earlier study, we analyzed 41 non-HLA SNPs that were associated with T1D by the Type 1 Diabetes Genetics Consortium and confirmed four SNPs (rs2476601 in *PTPN22*, rs2292239 in *ERBB3*, rs3184504 in *SH2B3*, and rs1004446 in *INS*) associated with IA and T1D [4]. In the current study, after adjusting for HLA, we used 131,847 SNPs from the TEDDY cohort to identify or confirm non-HLA genes associated with IA and T1D.


We found 3 known T1D regions (*PTPN22*, *INS*, *SH2B3*) and 2 novel regions (*PXK/PDHB* and *PPIL2*) associated with the development of any persistent confirmed islet autoantibody and/or multiple islet autoantibodies (Fig. 5). One known (*INS*) and one novel region (*TTC34/PRDM16*) was associated with IAA as first appearing autoantibody and one novel region (*RBFOX1*) was associated if the first appearing autoantibody was GADA. Specific mechanisms linking these loci to islet antibodies development remain to be determined. In analysis of T1D, we confirmed one region (*INS*)

previously associated with T1D and discovered three novel regions previously not known to be associated with T1D (*RNASET2*, *PLEKHA1*, and *PPIL2*) (Fig. 5).

PX domain containing serine/threonine kinase (*PXK*) was previously associated with susceptibility to systemic lupus erythematosus [22]. *PXK* operates on the B-cell antigen receptor (BCR) and influences the rate of BCR internalization [23]. Individuals carrying the risk haplotype exhibit a decreased rate of BCR internalization, a process known to impact B-cell survival and cell fate. Polymorphisms in the *PXK* gene were associated with autoantibody production, but not disease risk, of systemic lupus erythematosus in a Chinese population [24]. Other nearby genes in the region include *ABHD6*, *RPP14*, *PDHB*, *KCTD6* and *ACOX2*.

One region on chromosome 22 near the Peptidylprolyl Isomerase (Cyclophilin)-Like 2 (*PPIL2*) gene is associated with both IA production and T1D. This gene is a member of the cyclophilin family of peptidylprolyl isomerases. The cyclophilins are a highly conserved ubiquitously expressed family of proteins which play an important role in protein folding, immunosuppression by cyclosporin A, and infection by HIV-1 virions. The *PPIL-2* gene product is a protein that interacts with the proteinase inhibitor eglin c and is localized to the nucleus [25]. The highest expression levels of *PPIL2* was observed in thymus, testis, and islet cells in the pancreas. A recent proteome-scale profiling study identified *PPIL2* as a novel T1D-associated autoantigens [26]. Other nearby genes in the region are *UBE2L3*, *MAPK1*, *YDJC*, *YPEL1*, *CCDC116*, *SDF2L1*, *MIR301B* and *MIR130B*. A meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis, identified the *CCDC116* locus for both autoimmune disorders, but targeted *UBE2L3* as the most likely candidate gene [27]. The *UBE2L3* gene encodes for ubiquitin-conjugating enzyme E2 L3 and has been functionally linked with celiac disease, rheumatoid arthritis and SLE via the ubiquitination of the NF- κ B precursor. This gene plays a key role in

A: time-to-multiple IA Manhattan plot



B: K-M Plots





Fig. 2. Associations with risk of development of multiple islet autoantibodies. A: Manhattan plot of 131,847 SNPs with MAF>0.01, displaying the p -values on the $-\log_{10}$ scale for the SNPs associated with development of multiple islet autoantibodies in the TEDDY study population. Hazard Ratios and p -values are calculated using the Cox proportional hazards model to analyze each SNP's effect on the risk of T1D with adjustment for family history of T1D, HLA-DR-DQ genotype, gender, *HLA-DPB1*, population stratification (ancestral heterogeneity) and country of residence (as strata). The dashed line represents $p = 1 \times 10^{-5}$, the solid line represents Bonferroni correction threshold ($p = 3.7 \times 10^{-7}$). **B:** Kaplan-Meier plot of the most significant SNP from 2 known (*PTPN22*, *INS*) and 2 novel (*PPK*, *PPIL2*) regions are plotted by dividing the subjects in two groups: (i) Major homozygous (black curves) and (ii) Heterozygous combined with minor homozygous (red curves).

A: time-to-T1D Manhattan plot



B: K-M Plots




Fig. 3. Associations with risk of type 1 diabetes. **A:** Manhattan plot of 131,847 SNPs with MAF>0.01, displaying the p-values on the $-\log_{10}$ scale for the SNPs associated with **type 1 diabetes** in the TEDDY study population. Hazard Ratios and p-values are calculated using the Cox proportional hazards model to analyze each SNP's effect on the risk of T1D with adjustment for family history of T1D, HLA-DR-DQ genotype, gender, *HLA-DPB1*, population stratification (ancestral heterogeneity) and country of residence (as strata). The dashed line represents $p = 1 \times 10^{-5}$, the solid line represents Bonferroni correction threshold ($p = 3.7 \times 10^{-7}$). **B:** Kaplan-Meier plot of the most significant SNP from 1 known (*INS*) and 3 novel (*RNASET2*, *PLEKHA1* and *PPIL2*) regions are plotted by dividing the subjects in two groups: (i) Major homozygous (black curves) and (ii) Heterozygous combined with minor homozygous (red curves).




Fig. 4. Regional plots of four novel regions associated with risk of islet autoimmunity and type 1 diabetes in the TEDDY. Regional association plots at the four novel regions generated by LocusZoom, showing the significance of association with islet autoimmunity (A) multiple islet autoantibodies (B) type 1 diabetes (C, D, E). Colors represent HapMap CEU linkage disequilibrium r^2 values with the most significantly associated SNP (shown in purple).

immune response including antigen processing [28,29]. *MAPK1* (*ERK2*) is involved in signaling pathways required for CD8 T-cell proliferation and survival [30] and non-obese diabetic (NOD) mice show defects in signal transduction via these pathways [31]. *SDF2L1*

gene encodes endoplasmic reticulum protein involved in misfolded protein response in beta cells [32]. *MIR301* and *MIR130* are known to play roles in inflammatory response and autoimmunity [33–36].

S.No.	Nearby Genes	Lead SNP	IA	MIA	T1D	IAA-First	GADA-First
Known Regions							
1	PTPN22	rs6679677	2.17E-06	2.25E-06	1.24E-04	1.73E-04	0.007
2	INS / TH	rs3842727	2.82E-05	1.32E-07	3.13E-07	5.67E-06	0.252
3	SH2B3	rs3184504	3.58E-07	5.58E-04	0.121	0.001	2.22E-04
Novel Regions							
1	PXK/PDHB	rs11705721	8.03E-05	8.99E-06	0.006	0.010	0.032
2	RNASET2/ MIR3939	rs73043122	0.128	0.011	4.06E-06	0.723	0.729
3	PLEKHA1/ MIR3941	rs113306148	2.59E-04	2.00E-05	2.54E-06	0.141	5.52E-04
4	PPIL2	rs428595	9.64E-07	1.06E-05	2.31E-06	0.017	0.111
5	TTC34 /PRDM16	rs28600853	0.056	0.351	0.792	6.45E-06	0.529
6	RBFOX1	rs9934817	5.56E-04	0.012	0.009	0.605	8.02E-06

Fig. 5. Summary of three known and six novel regions associated with risk of islet autoimmunity and type 1 diabetes in the TEDDY. Data were analyzed to discover the SNPs associated with five outcomes: (i) time to any persistent confirmed islet autoantibody (IA), (ii) time to multiple autoantibodies (MIA), (iii) time to type 1 diabetes (T1D), (iv) time to IAA as the first appearing antibody (IAA-First), (v) time to GADA as the first appearing antibody (GADA-First). P-values are listed for each SNP and cells with $p < 10^{-5}$ are highlighted.

Another novel region associated with T1D is 6q27 near *RNASET2* (Ribonuclease T2), a member of the Rh/T2/S-glycoprotein class of extracellular ribonucleases. This gene is known to be associated with Graves disease and vitiligo [37–39]. Other genes in this region include *CCR6*, *RPS6KA2-AS1*, *GPR31*, *TCP10L2*, *FGFR10P* and microRNA *MIR3939*. There is established evidence on the role of *FGFR10P* in Crohn's disease, an inflammatory bowel disease of the gastrointestinal tract [40]. *RPS6KA2* is associated with inflammatory bowel disease [41] and epigenetic modification (DNA methylation) in *RPS6KA2* has been associated with proliferative diabetic retinopathy in T1D patients [42]. C-C chemokine receptor type 6 (*CCR6*) is implicated in a host of immunological responses such as B-cell maturation and differentiation, recruitment of T cells and dendritic cells during an immunological response. In mouse model of T1D, *CCR6* expression dramatically decreased upon resveratrol (antioxidant) administration, subsequently inhibiting *CCR6* mediated migration and recruitment of inflammatory cells [43]. G-protein coupled receptor 31 (*GPR31*) is involved in the 12 lipooxygenase (LO) pathway in the β cell. In response to elevated blood glucose levels, free fatty acids and pro-inflammatory cytokines, LO activation engenders pro-inflammatory lipid intermediates such as 12-HPETE and 12-HETE. Activation of *GPR31* by 12-HETE ensues signaling pathways that inhibit antioxidant production, increase reactive oxygen species and oxidative stress, and ultimately β cell death [44].

The 10q26.13 region near *PLEKHA1* and microRNA *MIR3941* is also a novel region associated with T1D. Other nearby genes in the region are *BTBD16*, *ARMS2*, *HTRA1* and *DMBT1*. We found only one SNP with suggestive evidence in this region. *PLEKHA1* (or *TAPP1*) encodes a pleckstrin homology domain-containing adapter protein and it is shown that interaction of *TAPPs* with phosphatidylinositol (3,4)-bisphosphate regulates B-cell activation and autoantibody production [45]. In a recent study, *PLEKHA1* has been associated with T1D with supplementary evidence ($P = 9.92 \times 10^{-05}$) [46]. *DMBT1* is known to mediate interaction between tumor cells and immune response. In addition, *DMBT1* is a marker for endocrine (islet cells) differentiation in pancreas [47].

Consistent with findings in other TEDDY publications [1,9,10], this study also supports the observation that the different genomic factors are responsible for first appearing islet autoantibody. IAA as first appearing autoantibody was associated with one known region (*INS*) and one novel region near *MMEL1*, *TNFRS14*, *TTC34* and *PRDM16* genes. In a recent study, a non-synonymous SNP within

membrane metalloendopeptidase-like 1 (*MMEL1*) was associated with multiple sclerosis [48]. One SNP (rs9934817) within *RBFOX1* found to be associated only with GADA as first islet antibody. *RBFOX1* (RNA binding protein fox-1 homolog 1), an mRNA-splicing factor, is well known to play a pivotal role in neuronal development and have been shown to cause neurodevelopmental disorders [49]. Interestingly, a recent study indicate that beta cells share common splicing regulators with neurons and *RBFOX1* regulates the alternative splicing of key genes related to pancreatic beta cell function [50].

There are genetic overlaps across autoimmune disorders and some autoimmunity loci are shared among multiple diseases [51]. Most of the known and novel regions identified in this study are also common with other autoimmune diseases. The *PTPN22* region is known to be associated with T1D, rheumatoid arthritis, SLE, Hashimotos thyroiditis, Graves disease, Addisons disease, Myasthenia Gravis, vitiligo, systemic sclerosis and juvenile idiopathic arthritis [52,53]. The *SH2B3* region is known to be associated with T1D, celiac disease and hepatic autoimmunity [54,55]. The *PXK* region is known to be associated with SLE [22]. The novel region near *RNASET2* and *CCR6* on 6q27 is known to be associated with Graves disease, vitiligo and rheumatoid arthritis [37–39,56]. These observations suggest that several common pathways are involved in the loss of tolerance and the development of autoimmunity.

Genetic mapping studies for complex diseases like T1D were traditionally done with affected sibpair analyses and then increasingly by genome wide association studies using case-control study designs. A large number of susceptibility loci for various autoimmune diseases including T1D have been identified using these approaches [2,57–59]. However, a common finding of all these studies is that only a few genes have large effects on the phenotypes of interests. For T1D, over 40 loci have been identified with high statistical significance but none of the non-HLA loci has a large effect size in cross-sectional analyses (usually $RR < 1.5$). In contrast, time-to-event analysis may reveal relatively large effects, which are carried by low frequency (MAF 1–5%) variants [60]. For example, the HR for the *PPIL2* locus is 3.424 and HR for another novel locus, *RNASET2*, is 3.351. The HRs for two previously known regions, *PTPN22* and *INS*, are 1.59 and 0.60, respectively. These results suggest that prospective cohorts and survival analysis are powerful approaches for genetic mapping studies for complex diseases. A time-to-event analysis can have more power than a case-control analysis because time-to-event analysis includes

information over time for all subjects in the study population, whereas case-control is only a snapshot of time of the selected case and control subjects from the study population. In addition, The Cox proportional hazards model for time-to-event analysis can access instantaneous risk via hazard ratio while the logistic regression model for case-control analysis assesses the likelihood of an event occurring at a particular time via odds ratio. Time-to-event analysis can also estimate the event-free probability over time from the baseline hazard function given observable information.

It is worth noting that the results presented in this study are based on a subset of SNPs included in the Illumina ImmunoChip genotyping platform. Also, due to the limited number of events and short follow-up time, most of the findings have suggestive evidence. However, TEDDY is the largest longitudinal study focusing on the genetic and environmental factors for type 1 diabetes.

Interestingly, our study suggests that there are few genes involved in both IA and T1D. Indeed, in our analysis, only one known region (*INS*) and one novel region (*PPIL2*) were associated with both endpoints. The newly identified region (*PPIL2*) has been identified in association with multiple other autoimmune diseases. Further it contains genes encoding proteins with a plausible pathogenic roles for development of IA and T1D, including signaling pathways involved in inflammation and autoimmunity and the *PPIL2* protein, a recently identified T1D autoantigen. Further delineation of the key elements of this region will be an important area for future research.

We could confirm only 3 non-HLA associations and discovered 6 new regions which were previously not found using case/control studies. We hypothesize that as the TEDDY cohort is younger therefore genetic factors found in this study may confer the highest risk for the disease during early childhood. Also, these analyses are based on the high-risk population based HLA susceptibility and the findings may be different from the general population. Time-to-event analysis is more appropriate study design to identify predictors of disease, while case/control studies only identify associations. Replication studies and future analyses of the TEDDY cohort with more events and longer follow-up will likely provide more robust evidence for the newly suggested genetic factors.

Funding sources

The TEDDY Study is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 DK112243, UC4 DK117483, and Contract No. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR001082).

Acknowledgements

A complete list of the TEDDY Study Group can be found in the [Supplementary](#).

Appendix A. Supplementary data

Supplementary data related to this article can be found at


<https://doi.org/10.1016/j.jaut.2017.12.008>.

References

- [1] J.P. Krischer, K.F. Lynch, D.A. Schatz, J. Ilonen, A. Lernmark, W.A. Hagopian, et al., The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study, *Diabetologia* 58 (2015) 980–987.
- [2] C.A. Brorsson, F. Pociot, Type 1 diabetes genetics C. Shared genetic basis for type 1 diabetes, islet autoantibodies, and autoantibodies associated with other immune-mediated diseases in families with type 1 diabetes, *Diabetes Care* 38 (Suppl 2) (2015) S8–S13.
- [3] A.K. Steck, M.J. Rewers, Genetics of type 1 diabetes, *Clin. Chem.* 57 (2011) 176–185.
- [4] C. Torn, D. Hadley, H.S. Lee, W. Hagopian, A. Lernmark, O. Simell, et al., Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY study, *Diabetes* 64 (2015) 1818–1829.
- [5] A.K. Steck, F. Dong, R. Wong, A. Fouts, E. Liu, J. Romanos, et al., Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers, *Pediatr. Diabetes* 15 (2014) 355–362.
- [6] J. Lempainen, A.P. Laine, A. Hammaj, J. Toppari, O. Simell, R. Veijola, et al., Non-HLA gene effects on the disease process of type 1 diabetes: from HLA susceptibility to overt disease, *J. Autoimmun.* 61 (2015) 45–53.
- [7] A. Sharma, X. Liu, D. Hadley, W. Hagopian, E. Liu, W.M. Chen, et al., Identification of non-HLA genes associated with celiac disease and country-specific differences in a large, international pediatric cohort, *PLoS One* 11 (2016), e0152476.
- [8] W.A. Hagopian, H. Erlich, A. Lernmark, M. Rewers, A.G. Ziegler, O. Simell, et al., The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants, *Pediatr. Diabetes* 12 (2011) 733–743.
- [9] J.P. Krischer, K.F. Lynch, A. Lernmark, W.A. Hagopian, M.J. Rewers, J.X. She, et al., Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 Years of age: the TEDDY study, *Diabetes Care* 40 (2017) 1194–1202.
- [10] K.F. Lynch, H.S. Lee, C. Torn, K. Vehik, J.P. Krischer, H.E. Larsson, et al., Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident beta-cell autoantibodies, *J. Autoimmun.* (2017).
- [11] Group TS, The environmental Determinants of diabetes in the Young (TEDDY) study: study design, *Pediatr. Diabetes* 8 (2007) 286–298.
- [12] E. Bonifacio, L. Yu, A.K. Williams, G.S. Eisenbarth, P.J. Bingley, S.M. Marcovina, et al., Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia, *J. Clin. Endocrinol. Metab.* 95 (2010) 3360–3367.
- [13] N. Babaya, L. Yu, D. Miao, J. Wang, M. Rewers, M. Nakayama, et al., Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays, *Diab Metab Res Rev* 25 (2009) 665–670.
- [14] C. Torn, P.W. Mueller, M. Schlosser, E. Bonifacio, P.J. Bingley, L. Participating, Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2, *Diabetologia* 51 (2008) 846–852.
- [15] M. Schlosser, P.W. Mueller, C. Torn, E. Bonifacio, P.J. Bingley, L. Participating, Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies, *Diabetologia* 53 (2010) 2611–2620.
- [16] American Diabetes A, Executive summary: standards of medical care in diabetes—2011, *Diabetes Care* 34 (Suppl 1) (2011) S4–S10.
- [17] T. Therneau, A Package for Survival Analysis in S, 2015.
- [18] R.J. Pruim, R.P. Welch, S. Sanna, T.M. Teslovich, P.S. Chines, T.P. Gliedt, et al., LocusZoom: regional visualization of genome-wide association scan results, *Bioinformatics* 26 (2010) 2336–2337.
- [19] J.C. Barrett, D.G. Clayton, P. Concannon, B. Akolkar, J.D. Cooper, H.A. Erlich, et al., Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes, *Nat. Genet.* 41 (2009) 703–707.
- [20] M. Maziarz, W. Hagopian, J.P. Palmer, C.B. Sanjeevi, I. Kockum, N. Breslow, et al., Non-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies, *Gene Immun.* 16 (2015) 541–551.
- [21] S.S. Rich, B. Akolkar, P. Concannon, H. Erlich, J.E. Hilner, C. Julier, et al., Current status and the future for the genetics of type 1 diabetes, *Gene Immun.* 10 (Suppl 1) (2009) S128–S131.
- [22] J.E. Martin, S. Assassi, L.M. Diaz-Gallo, J.C. Broen, C.P. Simeon, I. Castellvi, et al., A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci, *Hum. Mol. Genet.* 22 (2013) 4021–4029.
- [23] S.E. Vaughn, C. Foley, X. Lu, Z.H. Patel, E.E. Zoller, A.F. Magnusen, et al., Lupus risk variants in the PXX locus alter B-cell receptor internalization, *Front. Genet.* 5 (2014) 450.
- [24] B. Yu, Q. Wu, Y. Chen, P. Li, Y. Shao, J. Zhang, et al., Polymorphisms of PXX are associated with autoantibody production, but not disease risk, of systemic lupus erythematosus in Chinese mainland population, *Lupus* 20 (2011) 23–27.
- [25] B.B. Wang, K.J. Hayenga, D.G. Payan, J.M. Fisher, Identification of a nuclear-specific cyclophilin which interacts with the proteinase inhibitor eglin c, *Biochem. J.* 314 (Pt 1) (1996) 313–319.
- [26] X. Bian, C. Wasserfall, G. Wallstrom, J. Wang, H. Wang, K. Barker, et al., Tracking the antibody immunome in type 1 diabetes using protein arrays, *J. Proteome Res.* (2016).

- [27] A. Zernakova, E.A. Stahl, G. Trynka, S. Raychaudhuri, E.A. Festen, L. Franke, et al., Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci, *PLoS Genet.* 7 (2011), e1002004.
- [28] S. Wang, I. Adrianto, G.B. Wiley, C.J. Lessard, J.A. Kelly, A.J. Adler, et al., A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus, *Gene Immun.* 13 (2012) 380–387.
- [29] M.J. Lewis, S. Vyse, A.M. Shields, S. Boeltz, P.A. Gordon, T.D. Spector, et al., UBE2L3 polymorphism amplifies NF-kappaB activation and promotes plasma cell development, linking linear ubiquitination to multiple autoimmune diseases, *Am. J. Hum. Genet.* 96 (2015) 221–234.
- [30] W.N. D'Souza, C.F. Chang, A.M. Fischer, M. Li, S.M. Hedrick, The Erk2 MAPK regulates CD8 T cell proliferation and survival, *J. Immunol.* 181 (2008) 7617–7629.
- [31] M. Mingueneau, S. Krishnaswamy, M.H. Spitzer, S.C. Bendall, E.L. Stone, S.M. Hedrick, et al., Single-cell mass cytometry of TCR signaling: amplification of small initial differences results in low ERK activation in NOD mice, *Proc. Natl. Acad. Sci. U S A* 111 (2014) 16466–16471.
- [32] A. Tiwari, I. Schuiki, L. Zhang, E.M. Allister, M.B. Wheeler, A. Volchuk, SDF2L1 interacts with the ER-associated degradation machinery and retards the degradation of mutant proinsulin in pancreatic beta-cells, *J. Cell Sci.* 126 (2013) 1962–1968.
- [33] J.K. Rieger, S. Reutter, U. Hofmann, M. Schwab, U.M. Zanger, Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9, *Drug Metabol. Dispos.* 43 (2015) 884–888.
- [34] X. Li, S. He, R. Li, X. Zhou, S. Zhang, M. Yu, et al., *Pseudomonas aeruginosa* infection augments inflammation through miR-301b repression of c-Myb-mediated immune activation and infiltration, *N. Microbiol.* 1 (2016) 16132.
- [35] M.P. Mycko, M. Cichalewska, A. Machlanska, H. Cwiklinska, M. Mariasiewicz, K.W. Selmaj, MicroRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination, *Proc. Natl. Acad. Sci. U S A* 109 (2012) E1248–E1257.
- [36] E. Caselli, M. D'Accolti, I. Soffritti, M.C. Zatelli, R. Rossi, E. Degli Uberti, et al., HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis, *Virology* 14 (2017) 3.
- [37] T. Raj, M. Kuchroo, J.M. Replogle, S. Raychaudhuri, B.E. Stranger, P.L. De Jager, Common risk alleles for inflammatory diseases are targets of recent positive selection, *Am. J. Hum. Genet.* 92 (2013) 517–529.
- [38] Q. Zhang, S. Liu, Y. Guan, Q. Chen, Q. Zhang, X. Min, RNASET2, GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves' disease, *J. Clin. Lab. Anal.* (2017).
- [39] Y. Jin, G. Andersen, D. Yorgov, T.M. Ferrara, S. Ben, K.M. Brownson, et al., Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants, *Nat. Genet.* 48 (2016) 1418–1424.
- [40] N.A. Restrepo, M. Butkiewicz, J.A. McGrath, D.C. Crawford, Shared genetic etiology of autoimmune diseases in patients from a biorepository linked to de-identified electronic Health records, *Front. Genet.* 7 (2016) 185.
- [41] A. Murphy, J.H. Chu, M. Xu, V.J. Carey, R. Lazarus, A. Liu, et al., Mapping of numerous disease-associated expression polymorphisms in primary peripheral blood CD4+ lymphocytes, *Hum. Mol. Genet.* 19 (2010) 4745–4757.
- [42] E. Agardh, A. Lundstig, A. Perflyev, P. Volkov, T. Freiburghaus, E. Lindholm, et al., Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy, *BMC Med.* 13 (2015) 182.
- [43] S.M. Lee, H. Yang, D.M. Tartar, B. Gao, X. Luo, S.Q. Ye, et al., Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes, *Diabetologia* 54 (2011) 1136–1146.
- [44] S.A. Tersey, E. Bolanis, T.R. Holman, D.J. Maloney, J.L. Nadler, R.G. Mirmira, Minireview: 12-lipoxygenase and islet beta-cell dysfunction in diabetes, *Mol. Endocrinol.* 29 (2015) 791–800.
- [45] I. Landego, N. Jayachandran, S. Wullschleger, T.T. Zhang, I.W. Gibson, A. Miller, et al., Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-biphosphate regulates B-cell activation and autoantibody production, *Eur. J. Immunol.* 42 (2012) 2760–2770.
- [46] Y. Qiu, Identification of novel risk genes associated with type 1 diabetes mellitus using a genome-wide gene-based association analysis, *J. Diab. Investig.* (2014).
- [47] R. Dodge, C. Loomans, A. Sharma, S. Bonner-Weir, Developmental pathways during in vitro progression of human islet neogenesis, *Differentiation* 77 (2009) 135–147.
- [48] M. Ban, J.L. McCauley, R. Zuvich, A. Baker, L. Bergamaschi, M. Cox, et al., A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MME1) is associated with multiple sclerosis, *Gene Immun.* 11 (2010) 660–664.
- [49] N. Hamada, H. Ito, T. Nishijo, I. Iwamoto, R. Morishita, H. Tabata, et al., Essential role of the nuclear isoform of RBFOX1, a candidate gene for autism spectrum disorders, in the brain development, *Sci. Rep.* 6 (2016) 30805.
- [50] J. Juan-Mateu, T.H. Rech, O. Villate, E. Lizarraga-Mollinedo, A. Wendt, J.V. Turatsinze, et al., Neuron-enriched RNA-binding proteins regulate pancreatic beta cell function and survival, *J. Biol. Chem.* 292 (2017) 3466–3480.
- [51] C. Richard-Miceli, L.A. Criswell, Emerging patterns of genetic overlap across autoimmune disorders, *Genome Med.* 4 (2012) 6.
- [52] S.M. Stanford, N. Bottini, PTPN22: the archetypal non-HLA autoimmunity gene, *Nat. Rev. Rheumatol.* 10 (2014) 602–611.
- [53] G.L. Burn, L. Svensson, C. Sanchez-Blanco, M. Saini, A.P. Cope, Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? *FEBS Lett.* 585 (2011) 3689–3698.
- [54] W. Hagopian, H.S. Lee, E. Liu, M. Rewers, J.X. She, A.G. Ziegler, et al., Co-occurrence of type 1 diabetes and celiac disease autoimmunity, *Pediatrics* 140 (2017).
- [55] G.J. Webb, G.M. Hirschfeld, Using GWAS to identify genetic predisposition in hepatic autoimmunity, *J. Autoimmun.* 66 (2016) 25–39.
- [56] Y. Kochi, Y. Okada, A. Suzuki, K. Ikari, C. Terao, A. Takahashi, et al., A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility, *Nat. Genet.* 42 (2010) 515–519.
- [57] J.P. Bradfield, H.Q. Qu, K. Wang, H. Zhang, P.M. Sleiman, C.E. Kim, et al., A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci, *PLoS Genet.* 7 (2011), e1002293.
- [58] Y.R. Li, S.D. Zhao, J. Li, J.P. Bradfield, M. Mohebbasab, L. Steel, et al., Genetic sharing and heritability of paediatric age of onset autoimmune diseases, *Nat. Commun.* 6 (2015) 8442.
- [59] G. Morahan, M. Mehta, I. James, W.M. Chen, B. Akolkar, H.A. Erlich, et al., Tests for genetic interactions in type 1 diabetes: linkage and stratification analyses of 4,422 affected sib-pairs, *Diabetes* 60 (2011) 1030–1040.
- [60] N.J. Schork, S.S. Murray, K.A. Frazer, E.J. Topol, Common vs. rare allele hypotheses for complex diseases, *Curr. Opin. Genet. Dev.* 19 (2009) 212–219.

Supplemental Figure-1



1. Number of Subjects excluded in quality control steps

- a. 59 subjects with low call rate (< 95%)
- b. 58 subjects having discordance with reported gender
- c. 20 subjects having discordance with prior genotyping

2. Number of SNPs excluded in quality control steps

REASON	Frequency	Percent
CallRateLessThan80	8678	32.52
CallRateLessThan95	3942	14.77
DiscordantInDuplic	217	0.81
HWDinEUR	858	3.22
INDELS	587	2.20
Monomorphic	12147	45.53
YInFemales	253	0.95
TOTAL Excluded	26682	100.00

CallRateLessThan80: SNP call rate less than 80%

DiscordantInDuplications: 2 or more pairs of identical twins have discordant genotypes at this SNP

Monomorphic: there is only 1 allele at this locus

INDELS: CNV, not SNPs



CallRateLessThan95: SNP call rate less than 95%



HWDinEUR: Hardy-Weinberg Equilibrium P value < 1E-6 in European subjects

S3: Table of all SNPs with $p < 10^{-5}$													
Known	Region	Genes	SNP	Major/Minor allele	CHR	BP	MAF	HR-IA	P-IA	HR-Multi IA	P-Multi-IA	HR-T1D	P-T1D
Known	1	PTPN22	rs6679677	C/A	1	114105331	0.114	1.46	2.17E-06	1.592	2.25E-06	1.635	1.24E-04
Known	1	PTPN22	rs2476601	G/A	1	114179091	0.114	1.46	2.33E-06	1.590	2.41E-06	1.632	1.31E-04
Known	2	INS / TH	rs3842752	G/A	11	2137649	0.201	0.76	4.72E-04	0.607	8.75E-06	0.466	2.39E-06
Known	2	INS / TH	rs3842748	G/C	11	2137971	0.204	0.74	2.12E-04	0.595	4.49E-06	0.454	1.48E-06
Known	2	INS / TH	rs3842729	G/A	11	2140912	0.200	0.76	5.63E-04	0.604	7.75E-06	0.470	3.17E-06
Known	2	INS / TH	rs3842727	A/C	11	2141424	0.284	0.75	2.82E-05	0.601	1.32E-07	0.504	3.13E-07
Known	3	SH2B3	rs3184504	G/A	12	110368991	0.462	1.35	3.58E-07	1.301	5.58E-04	1.166	1.21E-01
Known	3	SH2B3	rs4766578	T/A	12	110388754	0.476	1.34	1.06E-06	1.294	7.25E-04	1.153	1.48E-01
Known	3	SH2B3	rs10774625	G/A	12	110394602	0.476	1.33	1.35E-06	1.290	8.20E-04	1.151	1.54E-01
Known	3	SH2B3	rs653178	A/G	12	110492139	0.465	1.34	8.50E-07	1.291	8.30E-04	1.150	1.57E-01
Known	3	SH2B3	rs11065987	A/G	12	110556807	0.410	1.33	1.23E-06	1.304	4.72E-04	1.139	1.90E-01
Known	3	SH2B3	rs11065991	G/A	12	110567545	0.398	1.35	9.23E-07	1.347	1.26E-04	1.188	8.86E-02
Known	3	SH2B3	rs17696736	A/G	12	110971201	0.420	1.31	5.23E-06	1.298	5.57E-04	1.090	3.85E-01
Known	3	SH2B3	rs17630235	G/A	12	111076069	0.403	1.34	7.36E-07	1.311	3.76E-04	1.123	2.44E-01
Known	3	SH2B3	rs11066188	G/A	12	111095097	0.403	1.34	9.54E-07	1.307	4.43E-04	1.120	2.56E-01
Known	3	SH2B3	rs11066320	G/A	12	111390798	0.418	1.30	7.48E-06	1.296	6.52E-04	1.115	2.72E-01
Novel	1	PXK/PDHB	rs11705721	A/G	3	58375454	0.321	1.27	8.03E-05	1.410	8.99E-06	1.322	5.66E-03
Novel	2	RNASET2/MIR3939	rs73043122	G/C	6	167303257	0.013	1.42	1.28E-01	1.919	1.12E-02	3.351	4.06E-06
Novel	3	PLEKHA1 / MIR3941	rs113306148	G/A	10	124149828	0.013	1.97	2.59E-04	2.463	2.00E-05	3.067	2.54E-06
Novel	4	ASCL2 / MIR4686	rs12276159	G/A	11	2194050	0.046	1.43	4.40E-03	1.518	8.07E-03	2.219	7.14E-06
Novel	4	ASCL2 / MIR4686	rs10831551	A/C	11	2194864	0.048	1.42	4.68E-03	1.494	1.00E-02	2.219	5.42E-06
Novel	4	ASCL2 / MIR4686	rs10831570	C/A	11	2199188	0.047	1.40	6.43E-03	1.500	1.02E-02	2.197	9.46E-06
Novel	4	ASCL2 / MIR4686	rs7483211	C/A	11	2200757	0.046	1.42	4.58E-03	1.515	8.41E-03	2.222	6.95E-06
Novel	4	ASCL2 / MIR4686	rs10765840	G/A	11	2206549	0.046	1.42	4.66E-03	1.514	8.56E-03	2.215	7.57E-06
Novel	4	ASCL2 / MIR4686	rs12278109	G/A	11	2225271	0.046	1.44	3.33E-03	1.540	5.61E-03	2.202	8.68E-06
Novel	4	ASCL2 / MIR4686	rs11021918	T/A	11	2225766	0.046	1.44	3.33E-03	1.540	5.61E-03	2.202	8.68E-06
Novel	4	ASCL2 / MIR4686	rs12279951	G/A	11	2226247	0.046	1.43	3.68E-03	1.534	6.09E-03	2.191	9.91E-06
Novel	5	PPIL2	rs428595	G/A	22	20346391	0.011	2.47	9.64E-07	2.720	1.06E-05	3.424	2.31E-06



A. SNPs associated with progression to persistent IA

Plotted SNPs







Plotted SNPs




B. SNPs associated with progression to multiple antibodies



Plotted SNPs



Plotted SNPs






Plotted SNPs |





C. SNPs associated with progression to T1D



Plotted SNPs |



Plotted SNPs





Plotted SNPs





D. SNPs associated with progression to IAA as the first appearing islet autoantibody

Plotted SNPs ||




Plotted SNPs |



E. SNPs associated with progression to GAD as the first appearing islet autoantibody

Plotted SNPs



The TEDDY Study Group

Colorado Clinical Center: Marian Rewers, M.D., Ph.D., PI^{1,4,5,6,10,11}, Kimberly Bautista¹², Judith Baxter^{9,10,12,15}, Ruth Bedoy², Daniel Felipe-Morales, Kimberly Driscoll, Ph.D.⁹, Brigitte I. Frohnert, M.D.^{2,14}, Marisa Gallant, M.D.¹³, Patricia Gesualdo^{2,6,12,14,15}, Michelle Hoffman^{12,13,14}, Rachel Karban¹², Edwin Liu, M.D.¹³, Jill Norris, Ph.D.^{2,3,12}, Adela Samper-Imaz, Andrea Steck, M.D.^{3,14}, Kathleen Waugh^{6,7,12,15}, Hali Wright¹². University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

Finland Clinical Center: Jorma Toppari, M.D., Ph.D., PI^{¥^1,4,11,14}, Olli G. Simell, M.D., Ph.D., Annika Adamsson, Ph.D.^{^12}, Suvi Ahonen^{*±§}, Heikki Hyöty, M.D., Ph.D.^{*±6}, Jorma Ilonen, M.D., Ph.D.^{¥¶3}, Sanna Jokipuu[^], Tiina Kallio[^], Leena Karlsson[^], Miia Kähönen^{μx}, Mikael Knip, M.D., Ph.D.^{*±5}, Lea Kovanen^{*±§}, Mirva Koreasalo^{*±§2}, Kalle Kurppa, M.D., Ph.D.^{*±13}, Tiina Latva-aho^{μx}, Maria Lönnrot, M.D., Ph.D.^{*±6}, Elina Mäntymäki[^], Katja Multasuo^{μx}, Tiina Niininen^{±*12}, Sari Niinistö^{±§2}, Mia Nyblom^{*±}, Petra Rajala[^], Jenna Rautanen^{±§}, Anne Riikonen^{*±§}, Minna Romo[^], Juulia Rönkä^{μx}, Satu Simell, M.D., Ph.D.^{¥13}, Tuula Simell, Ph.D.^{¥12}, Maija Sjöberg^{¥^12,14}, Aino Stenius^{μx12}, Maria Leppänen[^], Sini Vainionpää[^], Eeva Varjonen^{¥^12}, Riitta Veijola, M.D., Ph.D.^{μx14}, Suvi M. Virtanen, M.D., Ph.D.^{*±§2}, Mari Vähä-Mäkilä[^], Mari Åkerlund^{*±§}, Katri Lindfors, Ph.D.^{*13} ¥University of Turku, *University of Tampere, μUniversity of Oulu, ^Turku University Hospital, Hospital District of Southwest Finland, ±Tampere University Hospital, xOulu University Hospital, §National Institute for Health and Welfare, Finland, ¶University of Kuopio.

Georgia/Florida Clinical Center: Jin-Xiong She, Ph.D., PI^{1,3,4,11}, Desmond Schatz, M.D.^{*4,5,7,8}, Diane Hopkins¹², Leigh Steed^{12,13,14,15}, Jennifer Bryant, Jamie Thomas^{*6,12}, Janey Adams^{*12}, Katherine Silvis², Michael Haller, M.D.^{*14}, Melissa Gardiner, Richard McIndoe, Ph.D., Ashok Sharma, Stephen W. Anderson, M.D.[^], Laura Jacobsen, M.D.^{*14} Center for Biotechnology and Genomic Medicine, Augusta University. *University of Florida, ^Pediatric Endocrine Associates, Atlanta.

Germany Clinical Center: Anette G. Ziegler, M.D., PI^{1,3,4,11}, Andreas Beyerlein, Ph.D.², Ezio Bonifacio Ph.D.^{*5}, Anja Heublein, Michael Hummel, M.D.¹³, Sandra Hummel, Ph.D.², Annette Knopff⁷, Charlotte Koch, Sibylle Koletzko, M.D.^{¶13}, Claudia Ramminger, Roswith Roth, Ph.D.⁹, Marlon Scholz, Laura Schulzik², Joanna Stock^{9,12,14}, Katharina Warncke, M.D.¹⁴, Lorena Wendel, Christiane Winkler, Ph.D.^{2,12,15}. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, Forschergruppe Diabetes, and Klinikum rechts der Isar, Technische Universität München. *Center for Regenerative Therapies, TU Dresden, ¶Dr. von Hauner Children's Hospital, Department of Gastroenterology, Ludwig Maximilians University Munich.

Sweden Clinical Center: Åke Lernmark, Ph.D., PI^{1,3,4,5,6,8,10,11,15}, Daniel Agardh, M.D., Ph.D.¹³, Carin Andrén Aronsson, Ph.D.^{2,12,13}, Maria Ask, Jenny Bremer, Ulla-Marie Carlsson, Corrado Cilio, Ph.D., M.D.⁵, Emelie Ericson-Hallström, Annika Fors, Lina Fransson, Thomas Gard, Rasmus Bennet, Carina Hansson, Susanne Hyberg, Hanna Jisser, Fredrik Johansen, Berglind Jonsdottir, M.D., Silvija Jovic, Helena Elding Larsson, M.D., Ph.D.^{6,14}, Marielle Lindström, Markus Lundgren, M.D.¹⁴, Maria Månsson-Martinez, Maria Markan, Jessica Melin¹², Zeliha Mestan, Caroline Nilsson, Karin Ottosson, Kobra Rahmati, Anita Ramelius, Falastin Salami, Sara Sibthorpe, Anette Sjöberg, Birgitta Sjöberg, Evelyn Tekum Amboh, Carina Törn, Ph.D.^{3,15}, Anne Wallin, Åsa Wimar¹⁴, Sofie Åberg. Lund University.

Washington Clinical Center: William A. Hagopian, M.D., Ph.D., PI^{1,3,4, 5, 6,7,11,13, 14}, Michael Killian^{6,7,12,13}, Claire Cowen Crouch^{12,14,15}, Jennifer Skidmore², Ashley Akramoff, Jana Banjanin, Masumeh Chavoshi, Kayleen Dunson, Rachel Hervey, Shana Levenson, Rachel Lyons, Arlene Meyer, Denise Mulenga, Davey Schmitt, Julie Schwabe. Pacific Northwest Research Institute.

Pennsylvania Satellite Center: Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith², Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children's Hospital of Pittsburgh of UPMC.

Data Coordinating Center: Jeffrey P. Krischer, Ph.D., PI^{1,4,5,10,11}, Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Rasheedah Brown^{12,15}, Brant Burkhardt, Ph.D.^{5,6}, Martha Butterworth², Joanna Clasen, David Cuthbertson, Christopher Eberhard, Steven Fiske⁹, Dena Garcia, Jennifer Garmeson, Veena Gowda, Kathleen Heyman, Belinda Hsiao, Francisco Perez Laras, Hye-Seung Lee, Ph.D.^{1,2,13,15}, Shu Liu, Xiang Liu, Ph.D.^{2,3,9,14}, Kristian Lynch, Ph.D.^{5,6,9,15}, Colleen Maguire, Jamie Malloy, Cristina McCarthy^{12,15}, Aubrie Merrell, Steven Meulemans, Hemang Parikh, Ph.D.³, Ryan Quigley, Cassandra Remedios, Chris Shaffer, Laura Smith, Ph.D.^{9,12}, Susan Smith^{12,15}, Noah Sulman, Ph.D., Roy Tamura, Ph.D.^{1,2,13}, Ulla Uusitalo, Ph.D.^{2,15}, Kendra Vehik, Ph.D.^{4,5,6,14,15}, Ponni Vijayakandipan, Keith Wood, Jimin Yang, Ph.D., R.D.^{2,15}. *Past staff: Michael Abbondandolo, Lori Ballard, David Hadley, Ph.D., Wendy McLeod.* University of South Florida.

Project scientist: Beena Akolkar, Ph.D.^{1,3,4,5,6,7,10,11}. National Institutes of Diabetes and Digestive and Kidney Diseases.

Autoantibody Reference Laboratories: Liping Yu, M.D.^{^5}, Dongmei Miao, M.D.[^], Polly Bingley, M.D., FRCP*⁵, Alistair Williams*, Kyla Chandler*, Claire Williams*, Gifty George*, Sian Grace*, Ben Gillard*. [^]Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, *Bristol Medical School, University of Bristol UK.

HLA Reference Laboratory: William Hagopian³, MD, PhD, Masumeh Chavoshi, Pacific Northwest Research Institute, Seattle WA. (Previously Henry Erlich, Ph.D.³, Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children's Hospital Oakland Research Institute.)

SNP Laboratory: Stephen S. Rich, Ph.D.³, Wei-Min Chen, Ph.D.³, Suna Onengut-Gumuscu, Ph.D.³, Emily Farber, Rebecca Roche Pickin, Ph.D., John Davis, Jordan Davis, Dan Gallo, Jessica Bonnie, Paul Campolieto. Center for Public Health Genomics, University of Virginia.

Repository: Sandra Ke, Niveen Mulholland, Ph.D. NIDDK Biosample Repository at Fisher BioServices.

Other contributors: Kasia Bourcier, Ph.D.⁵, National Institutes of Allergy and Infectious Diseases. Thomas Briese, Ph.D.^{6,15}, Columbia University. Suzanne Bennett Johnson, Ph.D.^{9,12}, Florida State University. Eric Triplett, Ph.D.⁶, University of Florida.

Committees:

¹Ancillary Studies, ²Diet, ³Genetics, ⁴Human Subjects/Publicity/Publications, ⁵Immune Markers, ⁶Infectious Agents, ⁷Laboratory Implementation, ⁸Maternal Studies, ⁹Psychosocial, ¹⁰Quality Assurance, ¹¹Steering, ¹²Study Coordinators, ¹³Celiac Disease, ¹⁴Clinical Implementation, ¹⁵Quality Assurance Subcommittee on Data Quality.